Previous Close | 4.9900 |
Open | 4.9500 |
Bid | 4.5000 x 800 |
Ask | 5.0500 x 1800 |
Day's Range | 4.9500 - 5.0550 |
52 Week Range | 4.8100 - 10.0900 |
Volume | |
Avg. Volume | 28,970 |
Market Cap | 47.925M |
Beta (5Y Monthly) | 1.19 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.6560 |
Earnings Date | Aug 11, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 31.75 |
Subscribe to Yahoo Finance Plus to view Fair Value for ACHV
SEATTLE and VANCOUVER, British Columbia, July 28, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will report its second quarter financial results and provide an update on the cytisinicline development program on Thursday, August 11, 2022, at 4:30 PM EDT. To access the webcast, please use the
SEATTLE and VANCOUVER, British Columbia, July 01, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the Company has issued inducement grants of stock options to two new employees. Achieve’s Board of Directors approved the new employment inducement grants to purchase an aggregate of 15,000 shares of Ach
SEATTLE and VANCOUVER, British Columbia, June 29, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it has initiated screening of subjects for the ORCA-V1 Phase 2 clinical trial. ORCA-V1 will evaluate the efficacy and safety of 3mg cytisinicline dosed 3 times daily compared to placebo in approximately 150 a